JAK1 and non-small cell lung carcinoma: In WCLC 2022, a phase 2 trial reported that pembrolizumab plus itacitinib (a JAK1 inhibitor) was effective (ORR, 62%) and safe for metastatic NSCLC with PD–L1 TPS of at least 50% (72).